ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
0.5500
+0.0171 (3.21%)
May 5, 2025, 4:00 PM EDT - Market closed
ALX Oncology Holdings Employees
ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.
Employees
80
Change (1Y)
8
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,685,625
Market Cap
29.37M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 80 | 8 | 11.11% |
Dec 31, 2023 | 72 | 14 | 24.14% |
Dec 31, 2022 | 58 | 15 | 34.88% |
Dec 31, 2021 | 43 | 20 | 86.96% |
Dec 31, 2020 | 23 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ALXO News
- 3 days ago - ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 10 days ago - ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewsWire
- 10 days ago - ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints - GlobeNewsWire
- 2 months ago - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - GlobeNewsWire
- 2 months ago - ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - GlobeNewsWire
- 2 months ago - ALX Oncology to Host Virtual R&D Day on March 5, 2025 - GlobeNewsWire
- 3 months ago - ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - GlobeNewsWire